[
  {
    "ts": null,
    "headline": "Regeneron Falls, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
    "summary": "Regeneron stock fell Friday, but an analyst suggested the company could seek deals following a solid fourth-quarter report.",
    "url": "https://finnhub.io/api/news?id=419d5010b4b6430887c5b2375080bfc41d97c595c4308cf9a889ded9fd4551aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769807163,
      "headline": "Regeneron Falls, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
      "id": 138310367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock fell Friday, but an analyst suggested the company could seek deals following a solid fourth-quarter report.",
      "url": "https://finnhub.io/api/news?id=419d5010b4b6430887c5b2375080bfc41d97c595c4308cf9a889ded9fd4551aa"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...",
    "summary": "Regeneron Pharmaceuticals Inc (REGN) reports a 3% revenue increase, driven by robust sales of Dupixent and strategic pipeline developments, despite competitive pressures and rising R&D expenses.",
    "url": "https://finnhub.io/api/news?id=99c5848526fe127b019dc983a7093071105c223255507e434501bccd7eb7455d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769806961,
      "headline": "Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...",
      "id": 138310368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc (REGN) reports a 3% revenue increase, driven by robust sales of Dupixent and strategic pipeline developments, despite competitive pressures and rising R&D expenses.",
      "url": "https://finnhub.io/api/news?id=99c5848526fe127b019dc983a7093071105c223255507e434501bccd7eb7455d"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of commercial execution,” highlighted by continued growth in Dupixent, Libtayo, and EYLEA HD, as well as a slate of upcoming regulatory and clinical catalysts. On the company’s fourth-qua",
    "url": "https://finnhub.io/api/news?id=82b29cd2f3751b745bc9cd2834e695a543032c54440c0e6b6c0e96ee1f7f6d70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769790508,
      "headline": "Regeneron Pharmaceuticals Q4 Earnings Call Highlights",
      "id": 138307447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of commercial execution,” highlighted by continued growth in Dupixent, Libtayo, and EYLEA HD, as well as a slate of upcoming regulatory and clinical catalysts. On the company’s fourth-qua",
      "url": "https://finnhub.io/api/news?id=82b29cd2f3751b745bc9cd2834e695a543032c54440c0e6b6c0e96ee1f7f6d70"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
    "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
    "url": "https://finnhub.io/api/news?id=5c33e62ec9ac46c3e7a93a34534126ef0117bed0a6cd4d9b53bde2d7c0defdab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769789655,
      "headline": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
      "id": 138307366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
      "url": "https://finnhub.io/api/news?id=5c33e62ec9ac46c3e7a93a34534126ef0117bed0a6cd4d9b53bde2d7c0defdab"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say",
    "summary": "While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=eac58549a648e0f43580088196bdcb86c6eb496bceb6c24ea449e2f4ac20a06e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769787002,
      "headline": "Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say",
      "id": 138307449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=eac58549a648e0f43580088196bdcb86c6eb496bceb6c24ea449e2f4ac20a06e"
    }
  },
  {
    "ts": null,
    "headline": "REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth",
    "summary": "REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.",
    "url": "https://finnhub.io/api/news?id=e745d1a342e9e0c5f7d0e8b99987e00075381c3ae4ec73dfa5968b4b92863663",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769786700,
      "headline": "REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth",
      "id": 138307450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.",
      "url": "https://finnhub.io/api/news?id=e745d1a342e9e0c5f7d0e8b99987e00075381c3ae4ec73dfa5968b4b92863663"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
    "summary": "Regeneron stock yo-yoed after Friday's open on the potential for business development deals following a solid fourth-quarter report.",
    "url": "https://finnhub.io/api/news?id=711591fbec282b2e6c4d95a5e325fed03946ca833afe98f5cec73f90efc84809",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769786528,
      "headline": "Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
      "id": 138306298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock yo-yoed after Friday's open on the potential for business development deals following a solid fourth-quarter report.",
      "url": "https://finnhub.io/api/news?id=711591fbec282b2e6c4d95a5e325fed03946ca833afe98f5cec73f90efc84809"
    }
  },
  {
    "ts": null,
    "headline": "KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate",
    "summary": "Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.",
    "url": "https://finnhub.io/api/news?id=8a6920ed16bea20ba1f0be0ea59310ae665650308eba660ae60ee2b4789a2a04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769785860,
      "headline": "KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate",
      "id": 138307451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.",
      "url": "https://finnhub.io/api/news?id=8a6920ed16bea20ba1f0be0ea59310ae665650308eba660ae60ee2b4789a2a04"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript",
    "url": "https://finnhub.io/api/news?id=ff6a58635f204de487e270c41311e4b6aa548fbe91fa9b61fb66281c6bb3356f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769785832,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript",
      "id": 138309307,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ff6a58635f204de487e270c41311e4b6aa548fbe91fa9b61fb66281c6bb3356f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "2026-01-30. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
    "url": "https://finnhub.io/api/news?id=f9392306d169f37b58ca4d9501bbac24e81faaf0d9dbbb382bdef1db79bd0993",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769785255,
      "headline": "Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation",
      "id": 138309188,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "2026-01-30. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
      "url": "https://finnhub.io/api/news?id=f9392306d169f37b58ca4d9501bbac24e81faaf0d9dbbb382bdef1db79bd0993"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Geopolitical Tensions Loom While Investors Still Await Fed Rate Cut",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively tr",
    "url": "https://finnhub.io/api/news?id=c6f910df82b206c604915490ba91a6dbca426f253ade8a09c69368d9ff947694",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769782342,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Geopolitical Tensions Loom While Investors Still Await Fed Rate Cut",
      "id": 138307288,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively tr",
      "url": "https://finnhub.io/api/news?id=c6f910df82b206c604915490ba91a6dbca426f253ade8a09c69368d9ff947694"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell",
    "summary": "Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.",
    "url": "https://finnhub.io/api/news?id=022f1a084e23fa017c3273b8b88b93ce8452920c89f720da151214c15cb488c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769780847,
      "headline": "Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell",
      "id": 138305467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.",
      "url": "https://finnhub.io/api/news?id=022f1a084e23fa017c3273b8b88b93ce8452920c89f720da151214c15cb488c5"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi touts strong new launch sales amid looming Dupixent patent expiry",
    "summary": "The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.",
    "url": "https://finnhub.io/api/news?id=4cac086790692fb3f9edf6594ee23280928b2fd0e9c7862000c0c458f0705e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769777775,
      "headline": "Sanofi touts strong new launch sales amid looming Dupixent patent expiry",
      "id": 138305468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.",
      "url": "https://finnhub.io/api/news?id=4cac086790692fb3f9edf6594ee23280928b2fd0e9c7862000c0c458f0705e22"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron beats quarterly profit estimates on Dupixent strength",
    "summary": "Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.",
    "url": "https://finnhub.io/api/news?id=bf56fd82677aa71f0c2317ac8203f1d1bf2c8c9141628b6c258afe895ce0c5c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769776859,
      "headline": "Regeneron beats quarterly profit estimates on Dupixent strength",
      "id": 138305469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.",
      "url": "https://finnhub.io/api/news?id=bf56fd82677aa71f0c2317ac8203f1d1bf2c8c9141628b6c258afe895ce0c5c5"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=5735372d380791151ae88e3d3600c57dcbb496bdb69138b14fb5d6acf48f77f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769776801,
      "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
      "id": 138305470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=5735372d380791151ae88e3d3600c57dcbb496bdb69138b14fb5d6acf48f77f4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen gives up on its once-prized eczema drug",
    "summary": "The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.",
    "url": "https://finnhub.io/api/news?id=408b68c4174eb02c18612f15511d99b92ab6d1a83f8c3b53eeb1b20094f8fb85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769774220,
      "headline": "Amgen gives up on its once-prized eczema drug",
      "id": 138307367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.",
      "url": "https://finnhub.io/api/news?id=408b68c4174eb02c18612f15511d99b92ab6d1a83f8c3b53eeb1b20094f8fb85"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q4 Earnings Snapshot",
    "summary": "The Tarrytown, New York-based company said it had net income of $7.86 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $11.44 per share. The results beat Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=094e223c5a40688b9ad8ef3a101f96079ec57e982a259f505666df6e11a67e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769773635,
      "headline": "Regeneron: Q4 Earnings Snapshot",
      "id": 138304659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The Tarrytown, New York-based company said it had net income of $7.86 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $11.44 per share. The results beat Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=094e223c5a40688b9ad8ef3a101f96079ec57e982a259f505666df6e11a67e22"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ce61b1be6dbba13738f67a69a43867e266b2c4480cdddd01c676900dc4b2ba88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769773237,
      "headline": "Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025",
      "id": 138305471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ce61b1be6dbba13738f67a69a43867e266b2c4480cdddd01c676900dc4b2ba88"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results",
    "summary": "Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.",
    "url": "https://finnhub.io/api/news?id=044862c6515bf0f228b74eba12e415ea93a307146f852d880e93db49e665264e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769772600,
      "headline": "Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results",
      "id": 138304660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.",
      "url": "https://finnhub.io/api/news?id=044862c6515bf0f228b74eba12e415ea93a307146f852d880e93db49e665264e"
    }
  },
  {
    "ts": null,
    "headline": "Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week",
    "summary": "More earnings are due, as well as a reading on monthly supplier inflation. Here is what to watch: Today   Earnings: American Express, Chevron, Exxon Mobil, Regeneron, Verizon   Economic data: Producer-price index for December   Federal Reserve news: President Trump has said he plans to unveil his pick to lead the central bank this morning.",
    "url": "https://finnhub.io/api/news?id=2b42cbe580ef272d6b467a2b9914d0f1a2c5e4337847c46bf5c0bc1a509eb3b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769764799,
      "headline": "Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week",
      "id": 138304579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "More earnings are due, as well as a reading on monthly supplier inflation. Here is what to watch: Today   Earnings: American Express, Chevron, Exxon Mobil, Regeneron, Verizon   Economic data: Producer-price index for December   Federal Reserve news: President Trump has said he plans to unveil his pick to lead the central bank this morning.",
      "url": "https://finnhub.io/api/news?id=2b42cbe580ef272d6b467a2b9914d0f1a2c5e4337847c46bf5c0bc1a509eb3b0"
    }
  },
  {
    "ts": null,
    "headline": "Is Regeneron (REGN) Offering Value After Recent Share Price Softness?",
    "summary": "If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines from what the numbers are actually saying about value. The share price recently closed at US$749.44, with returns of 10.3% over 1 year, 0.3% over 3 years, and 51.1% over 5 years. However, the year-to-date move of a 3.5% decline and shorter-term returns of a 0.8% decline over 7 days and a 3.2% decline over 30 days show that the ride has not been perfectly smooth. Recent...",
    "url": "https://finnhub.io/api/news?id=b4294b51d2b14df5e457008699976ed8e0c8e2c8011ed28126b23f95ed89c750",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769735430,
      "headline": "Is Regeneron (REGN) Offering Value After Recent Share Price Softness?",
      "id": 138302076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines from what the numbers are actually saying about value. The share price recently closed at US$749.44, with returns of 10.3% over 1 year, 0.3% over 3 years, and 51.1% over 5 years. However, the year-to-date move of a 3.5% decline and shorter-term returns of a 0.8% decline over 7 days and a 3.2% decline over 30 days show that the ride has not been perfectly smooth. Recent...",
      "url": "https://finnhub.io/api/news?id=b4294b51d2b14df5e457008699976ed8e0c8e2c8011ed28126b23f95ed89c750"
    }
  }
]